tetano
Editor, Senior Moderator
Vaccine. 2017 Oct 4. pii: S0264-410X(17)31307-5. doi: 10.1016/j.vaccine.2017.09.059. [Epub ahead of print]
[h=1]Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.[/h] Sun P[SUP]1[/SUP], Crum-Cianflone NF[SUP]2[/SUP], Defang G[SUP]3[/SUP], Williams M[SUP]3[/SUP], Ganesan A[SUP]4[/SUP], Agan BK[SUP]5[/SUP], Lalani T[SUP]6[/SUP], Whitman T[SUP]4[/SUP], Brandt C[SUP]2[/SUP], Burgess TH[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] This study was to compare B and T memory cells elicited by a single dose monovalent 2009 influenza A (H1N1) vaccine (strain A/California/7/2009 H1N1) in HIV[SUP]+[/SUP] and HIV[SUP]-[/SUP] groups, and to analyze the impact of the prior seasonal vaccines to the immunogenicity of this vaccine.
[h=4]METHODS:[/h] Blood samples were collected before vaccination (day 0) and at days 28 and 180. Participants were categorized into HIV[SUP]-[/SUP]/LAIV, HIV[SUP]-[/SUP]/TIV and HIV[SUP]+[/SUP]/TIV subgroups according to the trivalent live-attenuated or inactivated (LAIV or TIV) seasonal influenza vaccines they received previously. The IgG[SUP]+[/SUP] memory B cells (B[SUB]Mem[/SUB]) and IFNγ[SUP]+[/SUP] T cells were measured against antigens including the H1N1 vaccine, the hemagglutinin (HA) and neuraminidase (NA) proteins or peptide pools of the pandemic and the seasonal H1N1 strains, respectively.
[h=4]RESULTS:[/h] Overall B[SUB]Mem[/SUB] responses increased significantly at day 28 but returned to baseline by day 180 in all three subgroups. The average frequency of the H1N1-specific B[SUB]Mem[/SUB] at day 28 for the HIV[SUP]-[/SUP]/LAIV, HIV[SUP]-[/SUP]/TIV and HIV[SUP]+[/SUP]/TIV groups was 2.14%, 1.26% and 1.67%, respectively, and the average fold change was 14.39, 3.81 and 3.93, respectively. The differences of B[SUB]Mem[/SUB] between HIV[SUP]-[/SUP]/LAIV and the two TIV subgroups were significant. For the IFNγ response, the overall spot counts ranged widely between 0 and 958/10[SUP]6[/SUP] PBMCs. The group average spot counts to H1N1 vaccine was 89, 102, and 30 at day 28 for HIV[SUP]-[/SUP]/LAIV, HIV[SUP]-[/SUP]/TIV and HIV[SUP]+[/SUP]/TIV subgroups, respectively. The average increase of IFNγ response at day 28 vs day 0 in all three subgroups did not reach 2-fold.
[h=4]CONCLUSION:[/h] Participants with a prior LAIV seasonal vaccine, as compared to a TIV seasonal vaccine, responded significantly better to the monovalent H1N1 vaccine. Excluding LAIV participants, no difference was seen between the HIV[SUP]+[/SUP] and HIV[SUP]-[/SUP] subject groups in terms of B[SUB]Mem[/SUB]. The B[SUB]Mem[/SUB] response declined at 6months.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] B memory cells; HIV-infected participants; IFNγ T cell responses; Pandemic H1N1 vaccine
PMID: 28987439 DOI: 10.1016/j.vaccine.2017.09.059
[h=1]Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.[/h] Sun P[SUP]1[/SUP], Crum-Cianflone NF[SUP]2[/SUP], Defang G[SUP]3[/SUP], Williams M[SUP]3[/SUP], Ganesan A[SUP]4[/SUP], Agan BK[SUP]5[/SUP], Lalani T[SUP]6[/SUP], Whitman T[SUP]4[/SUP], Brandt C[SUP]2[/SUP], Burgess TH[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] This study was to compare B and T memory cells elicited by a single dose monovalent 2009 influenza A (H1N1) vaccine (strain A/California/7/2009 H1N1) in HIV[SUP]+[/SUP] and HIV[SUP]-[/SUP] groups, and to analyze the impact of the prior seasonal vaccines to the immunogenicity of this vaccine.
[h=4]METHODS:[/h] Blood samples were collected before vaccination (day 0) and at days 28 and 180. Participants were categorized into HIV[SUP]-[/SUP]/LAIV, HIV[SUP]-[/SUP]/TIV and HIV[SUP]+[/SUP]/TIV subgroups according to the trivalent live-attenuated or inactivated (LAIV or TIV) seasonal influenza vaccines they received previously. The IgG[SUP]+[/SUP] memory B cells (B[SUB]Mem[/SUB]) and IFNγ[SUP]+[/SUP] T cells were measured against antigens including the H1N1 vaccine, the hemagglutinin (HA) and neuraminidase (NA) proteins or peptide pools of the pandemic and the seasonal H1N1 strains, respectively.
[h=4]RESULTS:[/h] Overall B[SUB]Mem[/SUB] responses increased significantly at day 28 but returned to baseline by day 180 in all three subgroups. The average frequency of the H1N1-specific B[SUB]Mem[/SUB] at day 28 for the HIV[SUP]-[/SUP]/LAIV, HIV[SUP]-[/SUP]/TIV and HIV[SUP]+[/SUP]/TIV groups was 2.14%, 1.26% and 1.67%, respectively, and the average fold change was 14.39, 3.81 and 3.93, respectively. The differences of B[SUB]Mem[/SUB] between HIV[SUP]-[/SUP]/LAIV and the two TIV subgroups were significant. For the IFNγ response, the overall spot counts ranged widely between 0 and 958/10[SUP]6[/SUP] PBMCs. The group average spot counts to H1N1 vaccine was 89, 102, and 30 at day 28 for HIV[SUP]-[/SUP]/LAIV, HIV[SUP]-[/SUP]/TIV and HIV[SUP]+[/SUP]/TIV subgroups, respectively. The average increase of IFNγ response at day 28 vs day 0 in all three subgroups did not reach 2-fold.
[h=4]CONCLUSION:[/h] Participants with a prior LAIV seasonal vaccine, as compared to a TIV seasonal vaccine, responded significantly better to the monovalent H1N1 vaccine. Excluding LAIV participants, no difference was seen between the HIV[SUP]+[/SUP] and HIV[SUP]-[/SUP] subject groups in terms of B[SUB]Mem[/SUB]. The B[SUB]Mem[/SUB] response declined at 6months.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] B memory cells; HIV-infected participants; IFNγ T cell responses; Pandemic H1N1 vaccine
PMID: 28987439 DOI: 10.1016/j.vaccine.2017.09.059